- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01378754
Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
A DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPY
Interstitial cystitis is a condition where a defect in the protective lining of the bladder causes the urinary symptoms such as urgency, frequency and pain/burning on urination. One way to help ease the symptoms of this disease is to fill the bladder full of water every 4 to 6 months.
Since this is a painful procedure an anesthesiologist will give you a drug that will make you unconscious for the procedure. General anesthesia can be given to you through an IV tube that is placed in a vein in your arm. There are only a few agents that induce sedation and these agents have certain disadvantages such as waking up slowly, low blood pressure, and pain at the injection site and a prolonged time to consciousness.
This study will be comparing doses of a new IV sedation induction agent drug to put you to sleep called fospropofol (Lusedra®).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female outpatients
-> 18-65 years of age,
- weight 60-90 kg,
- with an American Society of Anesthesiologists (ASA) physical status of P1 to P3 are eligible for enrollment.
- Female patients of child bearing age will have a negative urine pregnancy test result and have used an acceptable method of birth control for >1 month prior to study enrollment.
- Patients will be NPO >6 hours and scheduled for outpatient urological hydrodilation under general anesthesia.
- Patients also will not be enrolled in another study or have received an experimental drug in the prior 30 days.
Exclusion criteria are:
- hypersensitivity or allergy to any anesthesia, opioids, benzodiazepines or any drugs used in the study, failure to meet NPO status or an abnormal, clinically significant ECG finding.
- Another exclusion is the presence of a difficult airway that would prevent use of the laryngeal mask airway (LMA) or successful LMA insertion.
- Women who are breast feeding would also be excluded from participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 6.5 milligram per kilogram of Fospropofol (Lusedra®)
|
Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
|
Experimental: 10 milligram per kilogram of Fospropofol (Lusedra®)
|
Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
|
Experimental: 12 milligram per kilogram of Fospropofol (Lusedra®)
|
Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the differences in dose on the time to loss of consciousness and loss of reflex using the laryngeal mask airway (LMA).
Time Frame: 1 day
|
To evaluate the use, dosing, efficacy and safety of fospropofol (Lusedra®) for the induction of general anesthesia using the laryngeal mask airway (LMA) in outpatient urology patients receiving hydrodilation therapy.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the difference in dose on blood pressure and heart rate using the laryngeal mask airway (LMA)
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Grace Shih, MD, University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12588
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Cystitis
-
Asan Medical CenterCompletedChronic Interstitial CystitisKorea, Republic of
-
St. Louis UniversityTerminated
-
St. Louis UniversityCompletedInterstitial Cystitis
-
Northwell HealthWithdrawnInterstitial CystitisUnited States
-
CAMC Health SystemCompletedInterstitial CystitisUnited States
-
UroGen Pharma Ltd.CompletedInterstitial Cystitis | ICIsrael
-
St. Louis UniversityCompleted
-
Drexel University College of MedicineMedtronicCompleted
-
AllerganTARIS Biomedical, Inc.TerminatedInterstitial CystitisUnited States, Canada
Clinical Trials on Fospropofol (Lusedra®) 6.5
-
Eisai Inc.PPDCompletedCoronary Artery Bypass Surgery | Ischemic Coronary Artery Disease
-
Eisai Inc.Completed
-
Eisai Inc.Completed
-
Eisai Inc.CompletedAnesthesia | BronchoscopyUnited States
-
Eisai Inc.CompletedProcedural SedationUnited States
-
Sheppard Pratt Health SystemEnrolling by invitationBipolar DepressionUnited States
-
Mayo ClinicEisai Inc.TerminatedOrthopedic Surgery | Procedural Sedation | Regional Anesthesia BlockUnited States
-
Watson PharmaceuticalsMassachusetts General HospitalCompleted
-
Eisai Inc.CompletedColonic Polyps | ColonoscopyUnited States
-
S&D Pharma SK s.r.o.National Cancer Institute, SlovakiaCompleted